Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?

Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study

(2015) L Dickinson et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics

(2015) A Olagunju et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

(2015) José R Arribas et al.   LANCET INFECTIOUS DISEASES

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection

(2015) Janaki Amin et al.   PLoS One

Does pregnancy affect the pharmacokinetics of efavirenz?

(2014) Andrew Hill et al.   AIDS

Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy

(2014) Paul E. Sax et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects

(2014) Ivy Song et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers

(2014) Thomas N. Kakuda et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics of Efavirenz and Treatment of HIV-1 Among Pregnant Women With and Without Tuberculosis Coinfection

(2014) Kelly E. Dooley et al.   JOURNAL OF INFECTIOUS DISEASES

Does HIV antiretroviral therapy still need its backbone?

(2014) Manuel Battegay et al.   LANCET

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

(2014) François Raffi et al.   LANCET

Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa

(2014) Nicholas I. Paton et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efavirenz 400 mg daily remains non-inferior to 600 mg: 96 week data from the double-blind, placebo-controlled ENCORE1 study

(2014) Dianne Carey   Journal of the International AIDS Society

Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial

(2014) Karen Tashima et al.   AIDS Research and Therapy

Association Between Antiretroviral Exposure and Renal Impairment Among HIV-Positive Persons With Normal Baseline Renal Function: the D:A:D Studya

(2013) L. Ryom et al.   JOURNAL OF INFECTIOUS DISEASES

Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results

(2013) Joel E. Gallant et al.   JOURNAL OF INFECTIOUS DISEASES

Comparative Efficacy of Lamivudine and Emtricitabine: A Systematic Review and Meta-Analysis of Randomized Trials

(2013) Nathan Ford et al.   PLoS One

Association of tenofovir exposure with kidney disease risk in HIV infection

(2012) Rebecca Scherzer et al.   AIDS

Renal Impairment in Patients Receiving a Tenofovir-cART Regimen

(2012) Isabelle Poizot-Martin et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin

(2012) Kelly E. Dooley et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection

(2011) Richard Elion et al.   AIDS

Efficacy and Safety of Once-Daily Nevirapine- or Efavirenz-Based Antiretroviral Therapy in HIV-Associated Tuberculosis: A Randomized Clinical Trial

(2011) S. Swaminathan et al.   CLINICAL INFECTIOUS DISEASES

Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis

(2011) Diane V. Havlir et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systematic Review and Meta‐analysis: Renal Safety of Tenofovir Disoproxil Fumarate in HIV‐Infected Patients

(2010) Ryan D. Cooper et al.   CLINICAL INFECTIOUS DISEASES

Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV Activity

(2009) A A Mathias et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Designing and interpreting HIV noninferiority trials in naive and experienced patients

(2008) Andrew Hill et al.   AIDS